Eli Lilly Begins Clinical Testing Of Baricitinib For COVID-19
- April 13, 2020
Reuters (4/10, Singh) reports Eli Lilly said Friday that it began clinical testing of therapies for COVID-19. The company “said it had entered into an agreement with the National Institute of Allergy and Infectious Diseases to study the baricitinib drug to examine its efficacy and safety as a potential treatment for hospitalized patients” diagnosed with the virus.
Bloomberg Law (4/10, Silver, Subscription Publication) also reported.